Review
Copyright ©The Author(s) 2021.
World J Clin Oncol. Nov 24, 2021; 12(11): 983-999
Published online Nov 24, 2021. doi: 10.5306/wjco.v12.i11.983
Table 4 Ongoing clinical trials of radiotherapy and immune checkpoint inhibitor combination in locally advanced stage non-small cell lung cancer in the concomitant setting
Ref.
Phase
Design
No.of patients
Tumor stage
RT
ICI agent
Sequence
Status
ARCHON-1, NCT03801902[85]1; 2 RT armsICI + RT24Unresectable II-IIIConventional RT (60 Gy/30 fx); Hypofractionated RT (60 Gy/15 fx)DurvalumabConcomitant with definitive RTRecruiting
PARTICLE-D, NCT03818776[86]1; 2 RT arms (proton beam therapyICI + RT27Unresectable IIIRT 60 Gy/20 fx; RT 63 Gy/23 fxDurvalumabConcomitant with definitive RTRecruiting
NCT04013542[87]1ICI + RT20II-IIIConventional RT Ipilimumab + NivolumabConcomitant with definitive RT and consolidation (nivolumab)Recruiting
NCT03663166[88]1; 2Concomitant CRT + ICI +/- consolidative ICI50Unresectable III60 Gy/30 fxIpilimumab +/-NivolumabConcomitant definitive treatment +/- consolidative ICIRecruiting
SPRINT,NCT03523702[54]2ICI + RT (if PD-L1 ≥ 50%) ; CRT (if PD-L1 < 50%)63Unresectable III Conventional RTPembrolizumabConcomitant with definitive RTRecruiting
KEYNOTE-799, NCT03631784[89]2Concomitant ICI + CRT (platinum doublet) followed by ICI216Unresectable III60 Gy/30 fxPembrolizumabConcomitante and consolidativeActive, not recruiting
NCT04092283[90]3 randomizedConcomitant CRT + ICI vs CRT followed by ICI (CT: Cisplatin + VP16/ Taxol + Carboplatin/ Cisplatin + Pemetrexed)660Unresectable III60 Gy/30 fxDurvalumabConcomitant with definitive treatment vs adjuvant ICIRecruiting
PACIFIC 2, NCT03519971[91]3 randomized, double-blindedICI vs placebo concomitant to CRT (CDDP-VP16 vs Carbo-Taxol vs Cisplatin or Carbo + Pemetrexed)328Unresectable IIIConventional RT (60 Gy in 30 fx)DurvalumabConcomitant +/- consolidativeActive, not recruiting
NCT04026412[92]3 randomizedICI (nivolumab) + CRT followed by ICI (nivolumab + ipilimumab) vs ICI (nivolumab) + CRT followed by ICI (nivolumab) vs CRT followed by durvalumab1400Unresectable/inoperable III Conventional RTNivolumab; Ipilimumab; DurvalumabConcomitant + 2 consolidation regimens vs consolidation after CRTRecruiting